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Rapidly progressive amyotrophic lateral sclerosis is associated with microglial reactivity and
small heat shock protein expression in reactive astrocytes
Aims: Amyotrophic lateral sclerosis (ALS) is a chronic
neurodegenerative disease characterized by progressive
loss of motor neurons, muscle weakness, spasticity,
paralysis and death usually within 2–5 years of onset.
Neuroinflammation is a hallmark of ALS pathology
characterized by activation of glial cells, which respond
by upregulating small heat shock proteins (HSPBs), but
the exact underlying pathological mechanisms are still
largely unknown. Here, we investigated the association
between ALS disease duration, lower motor neuron
loss, TARDNA-binding protein 43 (TDP-43) pathology,
neuroinflammation and HSPB expression. Methods:
With immunohistochemistry, we examined HSPB1,
HSPB5, HSPB6, HSPB8 and HSP16.2 expression in cer-
vical, thoracic and sacral spinal cord regions in 12 ALS
cases, seven with short disease duration (SDD), five
with moderate disease duration (MDD), and ten age-
matched controls. Expression was quantified using
ImageJ to examine HSP expression, motor neuron
numbers, microglial and astrocyte density and phos-
phorylated TDP-43 (pTDP-43+) inclusions. Results:
SDD was associated with elevated HSPB5 and 8 expres-
sion in lateral tract astrocytes, while HSP16.2 expres-
sion was increased in astrocytes in MDD cases. SDD
cases had higher numbers of motor neurons and micro-
glial activation than MDD cases, but similar levels of
motor neurons with pTDP-43+ inclusions. Conclusions:
Increased expression of several HSPBs in lateral column
astrocytes suggests that astrocytes play a role in the
pathogenesis of ALS. SDD is associated with increased
microgliosis, HSPB5 and 8 expression in astrocytes,
and only minor changes in motor neuron loss. This
suggests that the interaction between motor neurons,
microglia and astrocytes determines neuronal fate and
functional decline in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive
neurological disorder in which motor neurons in the
motor cortex, brainstem and spinal cord degenerate,
leading to spasticity, muscle weakness and atrophy [1].
The onset of ALS is primarily diagnosed between 55
and 75 years of age [2] and characterized by focal
motor deficits that rapidly accumulate, often resulting
in paralysis and death due to respiratory failure within
2–5 years [3].
The majority of ALS cases are sporadic, although
genetic mutations are associated with familial forms of
the disease in 5–10% of cases [1]. Virtually all these
mutations affect genes involved in protein homoeostasis
(proteostasis) [4]. Although the exact cause of ALS is
unknown, defects in proteostasis may play an impor-
tant role in disease pathogenesis leading to the forma-
tion of toxic aggregates [5].
In response to increased or dysfunctional proteosta-
sis, cells upregulate heat shock proteins (HSPs) to pro-
tect against cellular damage that accumulates during
pathological conditions [6]. HSPs are also upregulated
after cellular stress, including heat, hypoxia, inflamma-
tion and oxidative stress [7]. Given the strong associa-
tion between protein aggregation, glial activation and
neurodegeneration, the expression and role of HSPs in
the central nervous system (CNS) is attracting attention
in many neurodegenerative disorders [8], especially as
studies show that HSPs can potentially act as neuro-
protective agents [9]. HSPs are classified into several
families, including the large HSPA (HSP70) and HSPD1
(HSP60) and the small heat shock proteins (HSPBs)
[10]. Several HSPs are constitutively expressed in the
CNS while others are only observed in pathological
conditions such as in Alzheimer’s disease, Parkinson’s
disease, Alexander’s disease, multiple sclerosis and
X-linked adrenoleucodystrophy [11–15].
HSPBs are a family of 11 highly conserved proteins
that act as molecular chaperones and cytoskeleton sta-
bilizers, exerting protective effects by reducing protein
misfolding and promoting degradation of misfolded pro-
teins [16]. The role of HSPBs in neurodegenerative dis-
orders is supported by studies showing that mutations
in HSPB1, 3, 5 and 8 are associated with distal heredi-
tary motor neuropathies and myofibrillar myopathies
characterized by protein inclusions [17]. In vitro,
HSPB1, 5 and 8 prevent superoxide dismutase (SOD1)
and TARDNA-binding protein 43 (TDP-43) aggregation
by promoting degradation and solubility [18,19]. In
vivo, experimental induction of an HSPB5/8 homologue
partially rescues TDP-43 aggregation and increases life
span in drosophila [20]. In support of a protective role
of HSPB in animal models of ALS, slow-progressing
SOD1G93A mice have fivefold higher expression of
HSPB5 when compared to fast-progressing SOD1G93A
mice [21].
Apart from their roles as molecular chaperones,
small HSPs also inhibit apoptosis and play key roles in
immune regulatory pathways [22,23]. For example,
HSPB5 induces an anti-inflammatory phenotype in
microglia and macrophages in vitro that switches to a
pro-inflammatory response in the presence of IFN-c
[24].
Initial results of a recent clinical trial suggest that
arimoclomol, an inducer of the heat shock response,
might slow progression and respiratory decline in ALS
patients [4]. While many studies hint at the protective
effects of HSPBs in neuroinflammatory diseases includ-
ing ALS, little is known about HSPB expression, and
how such expression is associated with motor neuron
damage and glial activation in ALS.
In this study, we compared HSPB1, 5, 6, 8 and
orphan small heat shock protein HSP16.2 [25] expres-
sion in spinal cords of non-neurological controls and
ALS patients with short disease duration (SDD) and
moderate disease duration (MDD). We show that HSPB
expression by motor neurons and astrocytes is altered




Formalin-fixed, paraffin-embedded spinal cord tissue
from 12 ALS cases (mean age = 65.8 years), 7 SDD
(<18 months survival; mean survival = 11.1 
3.4 months) and 5 MDD (>24 months survival; mean
survival = 62.8  33.8 months) and 10 non-neurolo-
gical controls (mean age = 64.9 years) was collected at
post mortem in the pathology department of the Aca-
demic Medical Center (University of Amsterdam), with
the approval of the AMC Medical Ethical Committee
and according to local legal and ethical regulations.
Patients or relatives gave informed consent for autopsy
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and use of spinal cord tissue for research purposes. Tis-
sue samples from cervical levels (1 sample per case),
thoracic (two samples per case – except for cases 5 and
18 where one sample was available) and lumbar (one
sample per case) were examined. Patient characteristics
are listed in Table 1. Genetic analysis for 235 common
mutations implicated in ALS revealed one case with a
valosin-containing protein mutation (case 8); and a
C9ORF72 repeat expansion was detected in one case
(case 12).
Immunohistochemistry
Paraffin sections were deparaffinized with xylene,
rehydrated in graded ethanol solutions and washed in
water. Endogenous peroxidase was blocked by incu-
bating the slides in phosphate-buffered saline (PBS)
containing 0.3% (v/v) hydrogen peroxide for 30 min.
After washing in PBS, heat-mediated antigen retrieval
was performed using either 0.01 M citrate buffer (pH
6) or ethylene diamine tetra-acetic acid buffer (pH 9).
After cooling and washing in PBS, slides were incu-
bated for 1 h or overnight with primary antibodies
(Table S1) directed to phosphorylated TDP-43 (pTDP-
43), human leucocyte antigen receptor D related
(HLA-DR), glial fibrillary acid protein (GFAP), alde-
hyde dehydrogenase 1 (ALDH1), vimentin, HSPB1,
HSPB5, HSPB6, HSPB8 and HSP16.2 (Table S1)
diluted in normal antibody diluent (Immunologic), at
room temperature. Sections were washed and incu-
bated with the secondary antibody (Table S1): goat-
anti-mouse horseradish peroxidase (HRP) Envision
(Dako, Glostrup, Denmark) for HSPB5 and goat-anti-
rabbit HRP Envision (Dako) for other HSPBs. After
washing with PBS, the staining was developed with
3,30-diaminobenzidine (DAB; Dako) at a 1:50 concen-
tration for 10 min. Slides were washed in tap water,
the nuclei counterstained with haematoxylin and sec-
tions dehydrated in ascending alcohol concentrations
and xylene, and mounted with Quick-D (Klinipath,
Olen, Belgium). Prior to the study, all the antibodies
and relevant isotype controls [14] were used to check
Table 1. Patient characteristics
Sex Age ALS form or NNC details Primary onset ALS DD (months) Cause of death PMD (h)
ALS
1 F 70 sALS Leg 6 (SDD) Respiratory failure 3:05
2 M 63 sALS Leg 7 (SDD) Respiratory failure <12
3 F 61 sALS Arm 12 (SDD) Euthanasia <12
4 M 60 sALS Arm 12 (SDD) Euthanasia <12
5 M 81 sALS Respiratory 12 (SDD) Respiratory failure <12
6 F 84 sALS Bulbar 13 (SDD) Euthanasia <12
7 F 56 sALS Leg 16 (SDD) Euthanasia <12
8 F 61 sALS (VCP mutation) Arm 27 (MDD) Euthanasia <12
9 M 43 sALS Arm 36 (MDD) Unknown <12
10 F 64 fALS Leg 57 (MDD) Pneumonia <12
11 M 68 sALS Arm 87 (MDD) Euthanasia <12
12 M 79 sALS (C9orf72 repeat expansion) Unknown 107 (MDD) Pneumonia <12
Controls
13 M 60 BRICKER bladder n.a. n.a. Lung embolism <24
14 M 63 Renal carcinoma n.a. n.a. Lung embolism <24
15 F 81 Cardiac ischemia n.a. n.a. Endocarditis <24
16 F 63 Adenocarcinoma n.a. n.a. Paralytic ileus <24
17 M 69 Oesophageal carcinoma n.a. n.a. Multi organ failure <24
18 F 78 Cholangiocarcinoma n.a. n.a. Multi organ failure <48
19 M 75 COPD, pneumonia n.a. n.a. Respiratory failure <24
20 F 59 Pleuritis carcinomatosa n.a. n.a. Respiratory failure <24
21 F 47 Pancreatic carcinoma n.a. n.a. Abdominal bleeding <12
22 F 54 Carcinoma of the gallbladder n.a. n.a. Acute heart failure <24
COPD, chronic obstructive pulmonary disease; ALS, amyotrophic lateral sclerosis; fALS, familial ALS; n.a., not applicable; NNC, non-neu-
rological controls; PMD, post mortem delay; MDD, moderate disease duration; sALS, sporadic ALS; SDD, short disease duration; VCP, val-
osin-containing protein.
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background and cross reactivity. Isotype controls did
not reveal background staining.
pTDP-43 and cresyl-violet staining
To identify motor neurons expressing pTDP-43 aggre-
gates spinal cord sections were stained with an antibody
directed to pTDP-43 (Table S1) as described above.
After development with DAB, sections were incubated
overnight with 1% cresyl-violet solution, washed and
dehydrated in ascending alcohol concentrations and
xylene, then mounted with Quick-D (Klinipath).
Double labelling
To identify cells expressing HSPBs, double labelling was
performed for HLA-DR (microglia), oligodendrocyte
transcription factor 2 (olig2) (oligodendrocytes) or
vimentin (astrocytes). Sections were stained with HSPs
as described above and after developing with DAB, the
slides were washed and incubated with the second pri-
mary antibody for 1 h or overnight (Table S1). When
primary antibodies were from the same species, the
antibody directed to the first antigen of choice was
detached by heating in citrate buffer for 15 min. After
washing, the appropriate secondary antibody, goat-anti-
mouse alkaline phosphatase (AP) or goat-anti-rabbit AP
(Table S1), was applied for 1 h. After washing twice
with PBS and once with tris-buffered saline, slides were
developed with liquid permanent red (LPR; Dako;
1:100) for 10 min. Slides were washed in tap water
and nuclei were counterstained with haematoxylin,
washed in water and mounted with Aquatex (Merck
Millipore, Darmstadt, Germany). Following omission of
primary antibodies, no staining was observed.
Quantitative and statistical analysis
Motor neuron and pTDP-43 pathology quantification Spinal
cord sections, immunostained for pTDP-43 and Harris’
haematoxylin, were digitalized using the Mirax slide
scanner system equipped with a 209 objective with a
numerical aperture of 0.75 (3DHISTECH, Budapest,
Hungary) and Sony DFW-X710 Fire Wire 1/3″ type
progressive SCAN IT CCD (pixel size: 4.65 9 4.65 lm2).
The scan resolution of all images at 209 was 0.23 lm.
After scanning, representative areas were annotated
manually by a blinded observer (RPG) using PANNORAMIC
VIEWER software (3DHISTECH) and subsequently
exported in the TIFF image format. To determine the
numbers of motor neurons and motor neurons
containing TDP-43 pathology, a second blinded observer
(JS) manually counted the defined areas using ImageJ
(Fiji; {HYPERLINK ‘https://fiji.sc’}) [26].
HLA-DR, GFAP, ALDH1, vimentin and HSP expression
quantification The extent of HLA-DR, GFAP, ALDH1,
vimentin and HSP expression in the lateral tracts and
ventral horns was assessed using ImageJ. Three pictures
of the left and right ventral horns and lateral
corticospinal tracts at each spinal cord level (cervical,
thoracic [29], lumbar) were taken by a blinded
observer (RPG) at 4009 magnification using an
Olympus BX41 microscope equipped with a Leica
MC170 HD camera (Leica Microsystems, Heidelberg,
Germany). Pictures were analysed using IMAGEJ software
to calculate the percentage of DAB+ pixels per image.
Arbitrary thresholds were set to eliminate background
expression. Next, brown DAB staining was separated
from blue haematoxylin staining and the percentage of
DAB+ area was determined using the macro supplied
(Appendix S1). Mean values were calculated from three
images per sample. Vimentin and ALDH1 expression
was mostly seen in astrocytes, but also to a lesser
extent in cells that morphologically resembled foamy
macrophages. To only quantify astrocyte reactivity,
ImageJ was used to manually remove these cells based
on morphology prior to quantification.
Statistical analysis Using GRAPHPAD PRISM 6 (GraphPad
Software, La Jolla, CA, USA; https://www.graphpad.c
om/scientific-software/prism/), motor neuron numbers,
ventral horn surface area, absolute numbers of TDP-
43+ motor neurons, fraction of motor neurons which
are TDP-43+ as well as HLA-DR, GFAP, ALDH1,
vimentin and HSP expression in the lateral tracts and
ventral horns was examined. The expression levels of
the separate spinal cord levels (one cervical, one to two
thoracic, one lumbar) were averaged resulting in mean
values for each case. Data were checked for normal
distribution and parametric or non-parametric tests
were used accordingly. Differences between ALS
patients and controls were evaluated using Student’s
t-test or Mann-Whitney U-test. Differences between the
subgroups with SDD and MDD and controls were
determined using analysis of variance or Kruskal–Wallis
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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H test. When P < 0.05 post hoc analysis was performed
using Tukey’s test or Dunn’s multiple comparisons test.
Results
Short ALS disease duration is associated with pTDP-
43 pathology and activated microglia but not motor
neuron loss
Spinal cords of ALS patients (SDD and MDD) and non-
neurological controls were characterized based on motor
neuron counts (Figure 1A), ventral horn surface area
(Figure 1B), TDP-43 pathology (Figure 1C,D) and HLA-
DR reactivity (Figure 1L,P). Compared to non-neurologi-
cal controls, ALS spinal cords contained fewer motor
neurons (26.4%; P = 0.0172; Figure 1A), but more
pTDP-43 pathology (+2406%; P < 0.0001; Figure 1C,
D). In patients with SDD, ventral horn motor neuron
numbers were not significantly lower (14.4%;
P = 0.1906; Figure 1A), and a significant number of
neurons were pTDP-43+ (+3001%; P = 0.0001; Fig-
ure 1C). In the pTDP-43+ motor neurons, the inclusions
were observed as round balls or smaller string-like
aggregates (Figure 1E,F). Motor neuron numbers
(43.1%; P = 0.0052; Figure 1A) and ventral horn
surface area (38.4%; P = 0.0067; Figure 1B) were sig-
nificantly decreased in patients with MDD. Ventral horn
surface area was significantly lower in MDD compared
to SDD (P = 0.0314; Figure 1B). The few remaining
motor neurons in MDD cases appeared dystrophic and
often contained extensive pTDP-43 inclusions (Fig-
ure 1G,H). In both SDD and MDD cases, approximately
25% of motor neurons were pTDP-43+ (Figure 1D).
HLA-DR expression as a marker of microglia and
macrophage activity (Figure 1L–P) revealed signifi-
cantly higher expression in the ventral horns (+212%;
P < 0.0001; Figure 1L) and lateral tracts (+392%;
P = 0.0009; Figure 1P) in SDD cases, but not in MDD
cases. Sparse HLA-DR+ cells were present and the sur-
rounding tissue appeared fibrotic (Figure 1O). HLA-
DR+ foamy cells were only observed in white matter
and predominantly in patients with SDD (Figure 1N).
Increased astrocyte reactivity in ventral horns in
ALS
To assess astrocyte reactivity, the expression of astro-
cyte markers vimentin, GFAP and ALDH1 was
compared between ALS cases (SDD and MDD) and con-
trols (Figure 2). The expression of vimentin was signifi-
cantly increased in ALS cases in the ventral horns
(Figure 2A–D; ALS P = 0.0009; SDD P = 0.0251;
MDD P = 0.0042) and lateral columns (Figure 2E–H;
ALS P = 0.0003; SDD P = 0.0144; MDD P = 0.0177)
compared to controls. An increased density of GFAP in
the ventral horns in ALS cases (P = 0.0272) and
specifically in those cases with moderate (P = 0.0218)
but not SDD (P = 0.2648) was observed (Figure 2I–L),
but no differences in expression were found in the lat-
eral tracts (Figure 2M–P). Similarly, the density of
ALDH1 was also increased in ALS cases (P = 0.0105)
and in cases with MDD (P = 0.0021) but not SDD
(P = 0.3026) in the ventral horns (Figure 2Q–T), but
not in the lateral columns (Figure 2U–X).
HSPB1 expression is lower in ventral horns of ALS
spinal cord
In controls, HSPB1 was present in cell bodies, axons
and processes, but not in nuclei of motor neurons
throughout the ventral and dorsal horns (Figure 3A,B).
In accordance with the motor neuron loss in ALS,
fewer HSPB1+ motor neurons were observed in the
ventral horns (data not shown) contributing to the
decreased HSPB1 expression in ALS (P = 0.0384; Fig-
ure 3C) although differences could not be attributed to
disease duration that is SDD (P = 0.2261) or MDD
(P = 0.1640). In one SDD case, HSPB1+ inclusions
were seen in the neuronal bodies (Figure 3F).
In control spinal cord, cells with an astrocyte-like
morphology constitutively expressed HSPB1 throughout
the white matter (Figure 3G) and grey matter in close
proximity to the central canal (Figure 3H). In most
ALS patients, HSPB1 expression was similar to controls
and colocalized with vimentin, but not olig2. Overall,
HSPB1 expression in the lateral tracts of ALS spinal
cord was similar to controls (Figure 3I), however, in a
small subset of ALS patients, many HSPB1+ astrocytes
were observed (Figure 2J) and occasionally HSPB1 was
highly expressed in the subpial region (Figure 3K,L).
ncreased HSPB5 and HSPB8 expression in astrocytes
in ALS cases with SDD
HSPB5, was not observed in the motor neurons in the
ventral horns of controls (Figure 4A–C) nor ALS cases
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(Figure 4C–F). Rather, expression in the ventral horns
was almost exclusively present in the cytoplasm of
olig2+ cells (Figure 4E). In three ALS SDD cases,
HSPB5 was diffusely expressed in the ventral horn in
regions close to the lateral tracts that contained
HSPB5+ astrocytes, and from which the processes
extended into the grey matter (Figure 4D,E). In con-
trast to the ventral horns, HSPB5 was expressed in
astrocyte-like cells throughout the white matter
(Figure 4G) and around the central canal (Figure 4H)
in controls. In comparison, HSPB5 was highly
expressed in ALS cases (P = 0.0006; Figure 4I), espe-
cially in SDD cases (P = 0.0055; Figure 4I,J,K). Such
expression was localized to nuclei, cell bodies and astro-
cytes, as confirmed by double staining with vimentin
(Figure 4L, insert).
Different from HSPB5, HSPB8 was strongly expressed
in cell bodies and axons of ventral horn neurons in
(A) (B) (C) (D)
(E) (F) (G) (H)
(I) (J) (K) (L)
(M) (N) (O) (P)
Figure 1. Motor neurons, pTDP-43 inclusions and microglial activation in ALS spinal cord. Quantification of (A) motor neuron counts,
(B) ventral horn surface, (C) number of pTDP-43+ inclusions and (D) percentage of pTDP-43+ inclusion containing motor neurons in
controls and ALS patients (subgroups: SDD and MDD). pTDP-43+ motor neurons in ALS patients with (E,F) SDD and (G,H) MDD. HLA-
DR expression in (I–K) ventral horns and (M–O) lateral tracts of controls and SDD and MDD patients. Quantification of HLA-DR+ pixels
in (L) ventral horns and (P) lateral tracts of controls and ALS patients (subgroups: SDD and MDD). Data points represent the mean value
for each patient. Data are shown as mean  SEM. Significance was analysed between ALS patients (n = 12) and controls (n = 10) with
Student’s t-test or Mann–Whitney U-test. ALS patients SDD (n = 7) and MDD (n = 5) were compared to controls (n = 10) using ANOVA
and Tukey’s post-test or Kruskal–Wallis H test and Dunn’s post hoc multiple comparisons test. Significant data are presented
(****P = <0.0001, ***P = <0.001, **<0.01, *P = <0.05). Scale bar in all pictures = 50 lm. Inserts are digitally enlarged. SDD, short
disease duration; MDD, moderate disease duration; ALS, amyotrophic lateral sclerosis; HLA-DR, human leucocyte antigen-D related; TDP,
TARDNA-binding protein; pTDP-43, phosphorylated TDP.
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Figure 2. Astrocyte reactivity in ALS spinal cord. Expression (A–C) and quantification (D) of vimentin+ pixels in ventral horns of controls
and ALS patients (subgroups: SDD and MDD). Expression (E–G) and quantification (H) of vimentin+ pixels in lateral columns of controls and
ALS patients (subgroups: SDD and MDD). Expression (I–K) and quantification (L) of GFAP+ pixels in ventral horns of controls and ALS
patients (subgroups: SDD and MDD). Expression (M–O) and quantification (P) of GFAP+ pixels in lateral columns of controls and ALS
patients (subgroups: SDD and MDD). Expression (Q–S) and quantification (T) of ALDH1+ pixels in ventral horns of controls and ALS patients
(subgroups: SDD and MDD). Expression (U–W) and quantification (X) of ALDH1+ pixels in lateral columns of controls and ALS patients
(subgroups: SDD and MDD). Data points represent the mean value for each patient. Data are shown as mean  SEM. Significance was
analysed between ALS patients (n = 12) and controls (n = 10) with Student’s t-test or Mann–Whitney U-test. ALS patients with short
disease duration (SDD; n = 7) and moderate disease duration (MDD; n = 5) were compared to controls (n = 10) using ANOVA and Tukey’s
post-test or Kruskal–Wallis H test and Dunn’s post hoc multiple comparisons test. Significant data are presented (****P = <0.0001,
***P = <0.001, **<0.01, *P = <0.05). Scale bar in all pictures = 50 lm. SDD, short disease duration; MDD, moderate disease duration;
ALS, amyotrophic lateral sclerosis; GFAP, glial fibrillary acid protein; ALDH1, aldehyde dehydrogenase 1.
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both controls and ALS (Figure 5A,B,D–F). Rarely,
HSPB8+ inclusions were observed (Figure 5F). HSPB8
was also expressed in occasional grey matter astrocytes
in controls and in two ALS patients with SDD. Overall,
ventral horn HSPB8 expression showed no difference





Figure 3. HSPB1 expression in ALS spinal cord. HSPB1 expression in (A,B,D–F) ventral horns and (G,H,J–L) lateral tracts of controls and
ALS patients (subgroups: SDD and MDD) with (L) an insert of a vimentin+ (pink) and HSPB1+ (brown) astrocyte. Grey matter is
delineated with a dotted line. Quantification of HSPB1+ pixels in (C) ventral horns and (I) lateral columns of controls and ALS patients
(subgroups: SDD and MDD). Data points represent the mean value for each patient. Data are shown as mean  SEM. Significance was
analysed between ALS patients (n = 12) and controls (n = 10) with Student’s t-test or Mann–Whitney U-test. ALS patients with SDD
(n = 7) and MDD (n = 5) were compared to controls (n = 10) using ANOVA and Tukey’s post-test or Kruskal–Wallis H test and Dunn’s post
hoc multiple comparisons test. Significant data are presented (****P = <0.0001, ***P = <0.001, **<0.01, *P = <0.05). Scale bar in all
pictures = 50 lm. Inserts are digitally enlarged. SDD, short disease duration; MDD, moderate disease duration; ALS, amyotrophic lateral
sclerosis; HSPB, heat shock protein B.
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HSPB8 expression was occasionally observed in nuclei
of cells with an astrocyte-like morphology (Figure 5G)
throughout the lateral tracts and the central canal
(Figure 5H). In ALS, the number of HSPB8+ vimentin+
astrocytes was higher in lateral tracts, and where
expression extended into astrocyte cell bodies and pro-
cesses (Figure 5J–L).
HSPB6 expression is constitutively expressed in the
spinal cord
Low expression of HSPB6 was observed in neuronal cell
bodies, axons and occasional grey matter astrocytes in
control (Figure 6A,B) and ALS cases (Figure 6D–F),
although no differences in HSPB6 expression were
detected (Figure 6C). HSPB6+ inclusions were not
observed.
In the lateral tracts of control cases, HSPB6 expres-
sion was observed in cells resembling astrocytes (Fig-
ure 6G), which was more pronounced adjacent to
blood vessels (Figure 6H). No differences in expression
between ALS and control cases were detected (Fig-
ure 6I); however, three ALS patients revealed relatively
high expression of HSPB6 in the lateral tracts (Fig-
ure 6J–L). Here, HSPB6 staining was both diffuse and
localized to astrocytes in areas of tissue damage (Fig-
ure 6J–L).
HSP16.2 expression is increased in lateral columns
in ALS with long disease duration
Extensive HSP16.2 expression was observed on the cell
membrane of neurons and axons throughout the grey
matter of controls (Figure 7A–C). Similar expression
was observed in ALS cases (Figure 7D–F) in the grey
matter but not in the ventral horns where staining was
less intense (non-significant; Figure 7C). The numbers
of sharply delineated HSP16.2+ motor neurons were
decreased (Figure 7E) and expression associated with
tissues with a fibrotic appearance (Figure 7F). No
HSP16.2+ inclusions were observed.
In controls, HSP16.2 expression was observed occa-
sionally in nuclei of astrocyte-like cells throughout the
lateral tracts (Figure 7G), surrounding the central
canal (data not shown) and occasionally in endothelial
cells (Figure 7H). HSP16.2 expression was significantly
higher in MDD cases compared to controls
(P = 0.0059; Figure 7I,K) and SDD cases (P = 0.9931;
Figure 7J). In some ALS cases and controls, HSP16.2
was also observed in the lumen of blood vessels (Fig-
ure 7L).
Discussion
Although motor neurons degenerate in ALS, the exact
pathological mechanisms underlying functional decline
and disease progression are unknown [27]. Here, we
investigated the association between ALS disease dura-
tion, motor neuron damage and expression of the
stress-inducible HSPBs as markers of glial activation
and inflammation in ALS spinal cord. We show that
although the motor neurons in ALS spinal cord do not
upregulate basal expression of HSPB1, 6, 8 and
HSP16.2, expression of several HSPBs is markedly
increased in astrocytes in the lateral columns through-
out the spinal cord. This suggests these cells play a role
in the pathogenesis of ALS. Moreover, we show that
SDD is associated with less motor neuron loss, more
microglial activity and increased HSPB5 and 8 expres-
sion. This possibly indicates a relationship in ALS
between stressors, such as increased proteostasis and
oxidative stress and astrocyte reactivity, microglial acti-
vation and survival.
HSPBs, including HSPB1, 5 and 8 may aid motor
neuron survival by preventing protein aggregation
[18–20]. Although HSPB1 and 8 mRNA levels have
previously been found to be increased in ALS ventral
horns [28], our study shows that only very few neu-
rons contained HSPB1+ or HSPB8+ inclusions. More-
over, we did not observe increased expression of HSPBs
in ventral horns during ALS, but rather a decrease in
expression of HSPB1. This could be due to loss of motor
neurons or decreased expression by residual motor neu-
rons, similar to decreased HSPB1 protein expression in
SOD1G93A mice, which precedes motor neuron degener-
ation [29]. Generally, the lack of HSPB upregulation in
ALS motor neurons is consistent with the concept that
motor neurons have a high threshold before upregulat-
ing HSPs in response to heat shock or protein inclu-
sions [30,31].
In contrast to expression of HSPB in the motor neu-
rons, a marked expression of HSPB5, 8 and HSP16.2
was observed in astrocytes in the lateral tracts. HSPB
upregulation in astrocytes is prominent in many neu-
rological diseases, for example multiple sclerosis, Alz-
heimer’s disease, Parkinson’s disease and X-linked
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adrenoleucodystrophy and is associated with astrocyte
reactivity [11,13–15]. In ALS, upregulation of HSPBs
in astrocytes in response to for example oxidative
stress, inflammation, neurotoxic protein aggregation or
neuronal damage may thus confer protection by exert-





Figure 4. HSPB5 expression in ALS spinal cord. HSPB5 expression in (A,B,D–F) ventral horns and (G,H,J–L) lateral tracts of controls and
ALS patients (subgroups: SDD and MDD) with inserts of (E) oligodendrocyte transcription factor 2 (olig2+) (pink) and HSPB5+ (brown)
oligodendrocytes and (L) a vimentin+ (pink) and HSPB5+ (brown) astrocyte. Grey matter is delineated with a dotted line. Quantification
of HSPB5+ pixels in (C) ventral horns and (I) lateral columns of controls and ALS patients (subgroups: SDD and MDD). Data points
represent the mean value for each patient. Data are shown as mean  SEM. Significance was analysed between ALS patients (n = 12)
and controls (n = 10) with Student’s t-test or Mann–Whitney U-test. ALS patients with SDD (n = 7) and MDD (n = 5) were compared to
controls (n = 10) using ANOVA and Tukey’s post-test or Kruskal–Wallis H test and Dunn’s post hoc multiple comparisons test. Significant
data are presented (****P = <0.0001, ***P = <0.001, **<0.01, *P = <0.05). Scale bar in all pictures = 50 lm. Inserts are digitally
enlarged. SDD, short disease duration; MDD, moderate disease duration; ALS, amyotrophic lateral sclerosis; HSPB, heat shock protein B.
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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[32]. Simultaneously, HSPBs might facilitate astrocyte
activation as their molecular chaperoning functions
are important in cytoskeletal maintenance and
reorganization [33]. HSPB5 associates with astrocytic
cytoskeletal proteins such as GFAP [34], and expres-





Figure 5. HSPB8 expression in ALS spinal cord. HSPB8 expression in (A,B,D–F) ventral horns and (G,H,J–L) lateral tracts of controls and
ALS patients (subgroups: SDD and MDD) with (K) an insert of a vimentin+ (pink) and HSPB8+ (brown) astrocyte. Grey matter is
delineated with a dotted line. Quantification of HSPB8+ pixels in (C) ventral horns and (I) lateral columns of controls and ALS patients
(subgroups: SDD and MDD). Data points represent the mean value for each patient. Data are shown as mean  SEM. Significance was
analysed between ALS patients (n = 12) and controls (n = 10) with Student’s t-test or Mann–Whitney U-test. ALS patients with SDD
(n = 7) and MDD (n = 5) were compared to controls (n = 10) using ANOVA and Tukey’s post-test or Kruskal–Wallis H test and Dunn’s post
hoc multiple comparisons test. Significant data are presented (****P = <0.0001, ***P = <0.001, **<0.01, *P = <0.05). Scale bar in all
pictures = 50 lm. Inserts are digitally enlarged. SDD, short disease duration; MDD, moderate disease duration; ALS, amyotrophic lateral
sclerosis; HSPB, heat shock protein B.
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been implicated in astrogliosis [35], which is promi-
nent in ALS [36,37]. The increase in HSPB was not
due to an increase in astrocyte numbers per se as
GFAP and ALDH1 levels did not differ from controls.
Astrocytes in ALS contain inclusions and exhibit an





Figure 6. HSPB6 expression in ALS spinal cord. HSPB6 expression in (A,B,D–F) ventral horns and (G,H,J–L) lateral tracts of controls and
ALS patients (subgroups: SDD and MDD) with (L) an insert of a vimentin+ (pink) and HSPB6+ (brown) astrocyte. Grey matter is
delineated with a dotted line. Quantification of HSPB6+ pixels in (C) ventral horns and (I) lateral columns of controls and ALS patients
(subgroups: SDD and MDD). Data points represent the mean value for each patient. Data are shown as mean  SEM. Significance was
analysed between ALS patients (n = 12) and controls (n = 10) with Student’s t-test or Mann–Whitney U-test. ALS patients with SDD
(n = 7) and MDD (n = 5) were compared to controls (n = 10) using ANOVA and Tukey’s post-test or Kruskal–Wallis H test and Dunn’s post
hoc multiple comparisons test. Scale bar in all pictures = 50 lm. Inserts are digitally enlarged. SDD, short disease duration; MDD,
moderate disease duration; ALS, amyotrophic lateral sclerosis; HSPB, heat shock protein B.
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death [8,38–42]. As astrogliosis may be a physiologi-
cal response necessary for tissue repair as well as
playing a pathogenic role, the actual role that HSPBs
play in astrocytes during ALS remains to be deter-
mined. Of note, not all HSPBs are consistently upregu-





Figure 7. HSP16.2 expression in ALS spinal cord. HSP16.2 expression in (A,B,D–F) ventral horns and (G,H,J–L) lateral tracts of controls
and ALS patients (subgroups: SDD and MDD) with (K) an insert of a vimentin+ (pink) and HSP16.2+ (brown) astrocyte. HSP16.2+ blood
vessels are indicated with arrows (H,L). Grey matter is delineated with a dotted line. Quantification of HSP16.2+ pixels in (C) ventral
horns and (I) lateral columns of controls and ALS patients (subgroups: SDD and MDD). Data points represent the mean value for each
patient. Data are shown as mean  SEM. Significance was analysed between ALS patients (n = 12) and controls (n = 10) with Student’s
t-test or Mann–Whitney U-test. ALS patients with SDD (n = 7) and MDD (n = 5) were compared to controls (n = 10) using ANOVA and
Tukey’s post-test or Kruskal–Wallis H test and Dunn’s post hoc multiple comparisons test. Significant data are presented
(****P = <0.0001, ***P = <0.001, **<0.01, *P = <0.05). Scale bar in all pictures = 50 lm. Inserts are digitally enlarged. SDD, short
disease duration; MDD, moderate disease duration; ALS, amyotrophic lateral sclerosis; HSP heat shock protein.
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HSPB5 and 8 are upregulated in patients with SDD,
HSP16.2 is increased in ALS cases with MDD, under-
scoring the functional diversity of the different HSPB
family members [16].
In our study, SDD is associated with increased
HSPB5 and 8 expression in astrocytes, increased activa-
tion of microglia and/or macrophages, and relatively
little motor neuron loss. That SDD cases have similar
levels of pTDP-43 pathology compared with MDD
patients, implying that neuronal pathology alone does
not explain disease progression in ALS. The limited
motor neuron pathology in SDD ALS could indicate
that in these particular cases, death was due to neuro-
muscular junction pathology, Wallerian degeneration
or respiratory failure, prior to extensive motor neuron
cell body loss in the spinal cord. In serum of ALS
patients, HSP70 and HSP90 levels are reported to be
high in early disease, but gradually decline with disease
progression [43]. Moreover, in animal models and
human cell lines, prolonged stress depletes cellular
levels of HSPs leading to maladaptation of the protein
quality control system [32,44]. Thus, reduced HSPB
expression and microglial activation in patients with
MDD may reflect an exhausted immune and stress
response resulting in a transition from acute to chronic
inflammation. Further studies are needed to further
characterize the inflammatory profile of glial cells in
ALS with SDD and MDD.
Examination of post mortem tissue limits the separa-
tion of causative factors from reactive responses. For
example, the heightened inflammatory response in
patients with SDD may be a feature of early ALS, or
alternatively a causative factor in disease progression.
As SDD is associated with relative preservation of neu-
rons and only moderate levels of pTDP-43 inclusions,
spinal cord neuronal pathology itself does not explain
the rapid clinical decline of these patients. In ALS
brain, the density of TDP-43 inclusions does not corre-
late with disease duration or with rate of progression
[45]. Rather, glial responses to motor neuron degener-
ation may determine disease severity. Indeed, several
studies in humans seeking factors contributing to dis-
ease progression have found an increased presence of
pro-inflammatory markers in CSF [46] and blood
[47,48] of patients with rapidly progressive ALS.
Moreover, a recent data-driven approach evaluating
the ALS transcriptome, neuropathology and genome
wide associations, underscored the link between
microglia activation and disease progression in ALS
[49]. Furthermore, reduction of microglial proliferation
in SOD1G93A mice is associated with less motor neu-
ron death, reduced disease progression and prolonged
survival [50]. Nevertheless, a recent study established
that in a TDP-43rNLS8 mouse model of ALS the micro-
glial response is subtle and neuroprotective [51]. The
same study observed robust microglial activity in
patients with SOD1 mutations in contrast to variable
microglial reactivity in sporadic ALS (sALS) patients.
The authors hypothesized that this observation is due
to the diverse nature of the toxic aggregates in sALS
patients, which may be due to unidentified mutations
and/or environmental factors. Given the current lack
of knowledge regarding the nature of the aggregates
in sALS cases it is difficult to test this hypothesis. Our
studies indicate that rather than the nature of the
aggregates, the level of microglial activation in sALS
patients is strongly associated with disease duration.
Conclusions
Our findings show that HSPBs are upregulated predom-
inantly in astrocytes in ALS. These findings support the
hypothesis that the interaction between motor neurons,
microglia and astrocytes determines neuronal fate and
thus functional decline in ALS. Modulating the patho-
genic response and harnessing the protective response
of innate immunity in the CNS may favourably impact
the disease course in ALS.
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